EZH2 and diffuse large B-cell lymphoma: For example, activating EZH2 mutations occur in 27% of patients with follicular lymphoma and 22% of diffuse large B‐cell lymphoma (DLBCL),17 drive the disease, and represent a specific target for pharmacologic inhibition.15, 18, 19